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Abstract Objective: We investigated whether the oral
administration of a low dose (75 lg) of midazolam, a
CYP3A probe, can be used tomeasure the in vivoCYP3A
activity.
Methods: Plasma concentrations of midazolam, 1¢OH-
midazolamand4¢OH-midazolamweremeasured after the
oral administration of 7.5 mg and 75 lg midazolam in 13
healthy subjects without medication, in four subjects
pretreated for 2 days with ketoconazole (200 mg b.i.d.), a
CYP3A inhibitor, and in four subjects pretreated for
4 days with rifampicin (450 mg q.d.), a CYP3A inducer.
Results: After oral administration of 75 lg midazolam,
the 30-min total (unconjugated + conjugated) 1¢OH-
midazolam/midazolam ratios measured in the groups
without co-medication, with ketoconazole and with rif-
ampicin were (mean±SD): 6.23±2.61, 0.79±0.39 and
56.1±12.4, respectively. No side eﬀects were reported by
the subjects taking this low dose of midazolam. Good
correlations were observed between the 30-min total
1¢OH-midazolam/midazolam ratio and midazolam
clearance in the group without co-medication (r2=0.64,
P<0.001) and in the three groups taken together
(r2=0.91, P<0.0001). Good correlations were also
observed between midazolam plasma levels and mid-
azolam clearance, measured between 1.5 h and 4 h.
Conclusion: A low oral dose of midazolam can be used to
phenotype CYP3A, either by the determination of total
1¢OH-midazolam/midazolam ratios at 30 min or by the
determination of midazolam plasma levels between 1.5 h
and 4 h after its administration.
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Introduction
Because of its abundance in the intestine and liver,
CYP3A, a term that in adults reﬂects the collective
activity of CYP3A4 and CYP3A5, plays a central role in
the metabolism of a wide variety of therapeutic com-
pounds [1]. Considering the large inter-individual and
intra-individual variability in CYP3A activity, a method
allowing the assessment of its activity in vivo is valuable.
Several methods for phenotyping CYP3A activity have
been proposed that include the administration of mi-
dazolam (MID), 14C-labelled erythromycin, dapsone,
alfentanil, nifedipine or lidocaine, or that measure the
hydroxylation of endogenous cortisol (for a review see
[1, 2, 3]). The most widely accepted and tested probes
are erythromycin and MID [1, 2, 3], both of which have
their own advantages and limits. The erythromycin
breath test involves the administration of a 14C isotope
of the drug, it does not measure the activity of the iso-
zyme CYP3A5, and as it is given IV, intestinal CYP3A
activity cannot be assessed [1, 2]. In contrast, MID is a
substrate of both CYP3A4 and CYP3A5 [1, 2, 3], and
its oral administration allows to measure both intesti-
nal and hepatic CYP3A activity. The simultaneous
administration of oral and intravenous MID has been
proposed as a means to examine the contributions of
intestinal and hepatic CYP3A [4]. Finally, erythromycin
is a P-glycoprotein substrate [5], while discrepant results
have been published on MID [5, 6].
C. B. Eap (&) Æ G. Cucchia Æ D. Zullino Æ K. P. Golay
A.-C. Aubert Æ P. Baumann
Unit of Biochemistry and Clinical Psychopharmacology,
Centre of Psychiatric Neurosciences, University Department
of Adult Psychiatry, Prilly-Lausanne, Switzerland
E-mail: Chin.Eap@inst.hospvd.ch
Tel.: +41-21-6436438
Fax: +41-21-6436444
T. Buclin
Department of Clinical Pharmacology,
University Hospital of Lausanne, Switzerland
E. Hustert Æ R. Kerb
EPIDAUROS Biotechnologie AG,
Am Neuland 1, Bernried, Germany
G. Bleiber Æ A. Telenti
Division of Infectious Diseases,
University Hospital of Lausanne, Switzerland
Eur J Clin Pharmacol (2004) 60: 237–246
DOI 10.1007/s00228-004-0762-z
Following oral administration, MID is oxidised to
1¢-OH midazolam (1OHMID) and 4¢-OH midazolam
(4OHMID) [1]. The validity of using MID as a
CYP3A phenotyping probe has been demonstrated in
several studies. For example, the total clearance of
MID correlated highly with hepatic CYP3A in vitro
content measured in ten liver transplant patients
(r=0.93, P<0.001) [7]. Several studies examined the
possibility of using a single blood sampling to estimate
MID clearance. One study found that a single sam-
pling of 1OHMID or 1OHMID/MID plasma ratios
(hereafter indicated as MR or metabolic ratio) cannot
predict MID clearance in healthy adults, one of the
possible reasons for this negative result being the
inclusion of some obese subjects [8]. In another study,
the plasma MR measured 30 min after an IV admin-
istration of MID correlated well with the hepatic
CYP3A content (n=17; r=0.87, P<0.001) [9]. How-
ever, data from non-induced donors (n=11) showed a
weaker correlation (r=0.55, P<0.05) [9]. However, a
study with eight healthy male volunteers receiving a
single oral dose of 7.5 mg MID, found that the 30-min
MR was highly correlated with plasma MID clearance
(r=0.89, P<0.0068) [10]. In another study with ten
healthy male individuals receiving a single oral dose
of 7.5 mg MID, a signiﬁcant correlation was found
between plasma MID clearance and the MR measured
1 h after blood intake (r=0.70, P<0.05) [11]. A
signiﬁcant correlation (r=0.67, P<0.001) has also been
found between total (unconjugated + conjugated) MR
and cyclosporin clearance, a CYP3A substrate, in 26
liver-transplant recipients [12]. Finally, a retrospective
analysis of data from 224 healthy volunteers found that
the concentrations of MID measured after an IV or
oral dose explained 80% and 91% of the constitutive
interindividual variability in MID AUC, respectively
[13].
The quantiﬁcation limit of standard analytical
methods requires the use of suﬃciently high, pharma-
cologically active doses of MID (about 2–7.5 mg) with
the major disadvantage of causing drowsiness, sedation
and even amnesic eﬀects in some subjects. Therefore,
we developed and validated a very sensitive gas
chromatography—mass spectrometry—negative chemi-
cal ionisation analytical procedure [14], which allows to
measure low levels of MID and OHMID, i.e. levels
reached after the administration of 75 lg MID (one
hundredth of the usual dose), which is not expected to
produce any central nervous eﬀects. The aim of the
present study was to determine whether such a low
dose, with the determination of the MR, could be used
as an in vivo probe to assess CYP3A activity. For this
purpose, the kinetics of oral doses of 7.5 mg and of
75 lg MID were measured in 21 healthy subjects.
Subjects were either free of drugs known as being
CYP3 inducers or inhibitors (group 1, n=13) or
received ketoconazole (group 2, n=4) or rifampicin
(group 3, n=4), a strong CYP3A inhibitor and
inducer, respectively.
Subjects and methods
Study design
The study population consisted of 21 healthy volunteers
(19 Caucasian, 1 North African, 1 black African; 8 male;
mean±SD, range: age 33±9 years, 23–55 years; weight
62±10 kg, 50–78 kg) who were all free of drugs with the
exception of a subject with an oral contraceptive. The
study was approved by the ethics committee of the
University Department of Psychiatry, and all subjects
gave their written informed consent to participate in the
study. They received an indemnity of SF 600 (Swiss
francs). Subjects had normal hepatic and renal func-
tions, as assessed by standard clinical laboratory tests
(ALT, ASP, AP, GGT, urea, creatinine) and were asked
not to drink grapefruit juice at least 1 week prior to the
study, during and between the blood sampling sessions.
The use of alcohol and caﬀeine-containing beverages
was not allowed during the session.
Subjects were separated into three groups. In the
ﬁrst group (n=13), the kinetics of MID and its
metabolites were measured during two sessions,
separated by an interval of at least 1 week and at the
most 3 weeks. They received orally 7.5 mg MID in one
session and 75 lg in the other. They were randomly
assigned to start either with the 75-lg dose (seven
subjects) or the 7.5-mg dose (six subjects) for the ﬁrst
session. In a second group (n=4), the kinetics of oral
MID (75 lg) and metabolites were measured during
two sessions, separated by an interval of time of at
least 1 week and at the most 3 weeks. Two days before
the second session, and during two days, the subjects
came to the centre (to ensure compliance) in order to
take ketoconazole (200 mg b.i.d.). In a third group
(n=4), the kinetics of oral MID (75 lg) and metabo-
lites were measured during two sessions, separated by
an interval of at least 1 week and at the most 3 weeks.
Four days before the second session, the subjects came
to the centre (to ensure compliance) to take rifampicin
(450 mg q.d.). At the end of the second session, after
the last blood sampling, subjects received a ﬁfth dose of
rifampicin. The day following the second session, the
kinetics of oral 7.5 mg MID was measured.
Blood sampling
During each session, at approximately 0800 hours,
after an overnight fast, an intravenous catheter was
inserted into a forearm vein, and a blood sample was
taken into a heparinised tube (time 0). The subjects
were asked to drink 100 ml water containing either
0.075 mg or 7.5 mg MID, prepared by diluting 75 ll of
a 1-mg/ml MID solution into 100 ml of water or 1.5 ml
of a 5-mg/ml MID solution into 100 ml of water,
respectively. The subjects then drank an additional
100 ml water to rinse the glass. After ingestion of 75 lg
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of MID, blood samples were taken at 0.5, 1, 1.5, 2, 3, 4
and 6 h. After ingestion of 7.5 mg MID, supplemental
blood samples were taken at 8 h and 24 h (the catheter
was removed after the blood sampling at 8 h, the
subjects returned home but were asked to come back to
the centre for the 24-h blood sample). All blood sam-
plings were performed with subjects in the supine po-
sition. The subjects were given a breakfast and a meal,
if awake, approximately 1.5 h and 4.5 hours, respec-
tively, after ingestion of the drug. Subjects with the
standard dose of MID were asked to lie on a bed until
the sedative eﬀects of MID became inconsequential. All
subjects were asked to refrain from walking for at least
90 min. After collection, the blood samples were cen-
trifuged within 1 h, and the plasma samples stored at
)20C until analysis.
Pharmacodynamic measurements
The attention-altering eﬀects of the low and therapeutic
dose of MID on pharmacodynamics were measured at
the time of blood samplings using the Digit Symbol
Substitution Test (DSS) [15]. All volunteers were trained
to perform the test prior to the beginning of the study. In
this test, the number of digits correctly substituted for by
simple symbols in 3 min was recorded (when asleep,
subjects were scored zero).
Determinations of MID and metabolites
Determination of unconjugated MID, 1OHMID and
4OHMID, and of total 1OHMID and 4OHMID (un-
conjugated+conjugated) was performed by means of
gas chromatography—negative chemical ionisation
mass spectrometry [14]. Total concentrations were
obtained by enzymatic hydrolysis of the glucuronic
conjugates. The limits of quantiﬁcation, as deﬁned by
the concentration for which the mean value of replicate
determination (n=8) was within 20% of the actual
value, the coeﬃcient of variation less than 20%, and
which gave a signal-to-noise ratio of at least 10, were
found to be 10 pg/ml for the three substances. Intra- and
interday coeﬃcients of variation determined at three
concentrations (100 pg/ml, 500 pg/ml, 2 ng/ml) ranged
from 1% to 8% for MID, from 2% to 13% for 1OH-
MID, and from 1% to 14% for 4OHMID [14]. The
percent theoretical concentrations, which represent the
accuracy of the method, were within ±8% for MID and
1OHMID, within ±9% for 4OHMID at 500 pg/ml and
2 ng/ml, and within ±28% for 4OHMID at 100 pg/ml
[14]. No interference from ketoconazole or rifampicin
was noted during the MID assay (data not shown).
MID ratios were calculated with unconjugated and with
total concentrations separately. Ratios were then
multiplied by 325.8 and divided by 341.8 (the former and
the latter values being the molecular weights of MID
and OHMID, respectively).
Data analysis
The concentrations of unconjugated MID, 1OHMID
and 4OHMID determined after each administration
were plotted against time, both individually, and as
geometrical means and standard deviations according to
condition (dosage level, co-medication with ketoconaz-
ole or rifampicin). The individual curves were then
characterised by their peak level (Cmax), time to peak
(tmax), terminal rate constant estimated by log-linear
regression (kz), and area under the curve calculated by
log-trapezoidal rule with extrapolation to inﬁnity
(AUCinf). The terminal half-life (t1/2) was taken as ln(2)/
kz, the apparent clearance (CL¢ or CL/F) as dose/AUCinf,
and the apparent volume during the terminal phase
(Vz¢ or Vz/F) as CL¢/kz. For MID, the term ‘‘apparent’’
denotes that the estimate is the ratio of the true clearance
or volume over the oral bioavailability; for metabolites, it
was further divided by the fraction of the dose metabo-
lised along the corresponding pathway. All calculations
were performed using the non-compartmental method
implemented in the program Kinetica (version 4.0,
Innaphase, Buckinghamshire, UK). For correlation be-
tween MID ratios or MID plasma levels with MID
clearance, the latter values were those calculated during
the session with the therapeutic dose, in the group of
13 subjects without co-medications and in the four sub-
jects with rifampicin, as the terminal phase was better
characterised with this higher dose and as the aim of the
study was to validate the use of MID ratios or MID
plasma levels measured after the low dose against
pharmacokinetic parameters determined with the usual
therapeutic dose. In the group of four subjects with
ketoconazole, clearance values used for the correlations
were those calculated during the 75-lg dose session
(subjects in that group did not receive the higher dose).
Correlations were done with the Spearman test. The
parameter values obtained in the same subjects under
diﬀerent conditions were compared using Friedman
nonparametric two-way analysis of variance, while
comparisons between diﬀerent groups of subjects were
performed using Kruskall-Wallis test (Statistix version 7,
Analytical Software, Tallahassee, FL). The diﬀerences
were appreciated considering a signiﬁcance level of
P<0.05.
Results
The mean plasma concentrations of MID and its
metabolites after oral administration of 75 lg or 7.5 mg
MID are shown in Fig. 1. Pharmacokinetic parameters
of MID, 1OHMID and 4OHMID, according to dose
and co-medication with either rifampicin or ketoconaz-
ole are provided in Table 1, Table 2 and Table 3,
respectively. The pharmacokinetic proﬁle associated
with the administration of the 75-lg dose was similar
to the proﬁle observed after 7.5 mg. Both sets of con-
centration curves displayed a slightly bi-exponential
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pattern. As expected, the terminal phase was better
characterised after the higher dose, which produced
residual concentrations still measurable 24 h after
administration (not shown). This probably explains the
somewhat longer half-life values calculated under 7.5 mg
(2.2 h versus 1.7 h, n.s.), and the corresponding impact on
the estimated apparent volume of distribution (383 l
versus 276 l, P=0.005). A similar problem related to
detection limit probably also explains the longer half-life
calculated for 1OHMID after the higher dose (2 h versus
1.3 h, P=0.002), while for this metabolite it was
the apparent clearance that changed accordingly (258
l/h versus 516 l/h, P=0.0003).
The pre-treatment of rifampicin induced an impres-
sive drop of MID concentration levels, both after the
75-lg and 7.5-mg doses. Thus, for the 7.5-mg dose,
rifampicin decreased the Cmax by 89%: (2.9 ng/ml versus
26 ng/ml, P=0.003) and the AUC by 95% (3.5 h·ng/ml
versus 67 h·ng/ml, P=0.003). Rifampicin had almost
no inﬂuence on the t1/2, as observed after the high dose
(2.3 h versus 2.2 h, n.s.). The t1/2 could be reliably
determined with the high dose of MID even with rif-
ampicin, as MID was still measurable 8 h (two subjects)
or 24 h (two subjects) after MID intake. No eﬀect of
rifampicin on MID t1/2 could be reliably assessed after
the low dose, due to the detection-limit problem [MID
was already undetected 2 h (one subject), 4 h (two sub-
jects) and 6 h (one subject) after MID intake]. Rifam-
picin had a major inﬂuence on MID apparent clearance
and distribution volume, both after the high dose
(2179 l/h versus 129 l/h, P=0.003; respectively 7149 l
versus 383 l, P=0.003) and the low dose (1089 l/h versus
128 l/h, P=0.009; respectively 1101 l versus 276 l,
P=0.009). The pre-treatment by ketoconazole markedly
decreased the apparent clearance by 85% (19 l/h versus
128 l/h, P=0.003) and distribution volume by 76% (67 l
versus 276 l, P=0.003), and prolonged the t1/2 of the
marker drug (2.7 h versus 1.7 h, P=0.01).
Total MR varied only moderately over 0.5–6 h after
administration, whatever the pre-treatment condition
(Fig. 2 for the 75-lg dose after 30 min without
pretreatment: mean±SD, geometric mean, range
6.23±2.61, 5.66, 1.88–11.0). It could hardly be deter-
mined at the last plasma sampling times after adminis-
tration of the lower dose under rifampicin, due to
plasma concentrations of MID below the limit of
quantiﬁcation (Fig. 2). The MR increased markedly
under rifampicin, both for the low and the higher dose
(for the 75-lg dose after 30 min: mean±SD, geometric
mean, range 56.1±12.4, 55.5, 47.3–64.9; P<0.05). It
decreased drastically after 75 lg MID under ketoco-
nazole (for the 75-lg dose after 30 min: mean±SD,
geometric mean, range 0.79±0.39, 0.71, 0.37–1.20). The
pharmacodynamic eﬀects of 75 lg and 7.5 mg MID,
with and without ketoconazole, and with and without
rifampicin, are shown in Fig. 3. As the 75-lg dose of
MID was not tested against placebo, the true pharma-
codynamic eﬀect of this low dose cannot be assessed.
However, no particular side eﬀects, including drowsi-
ness, were reported by the subjects taking this low dose,
with or without ketoconazole. As expected, with 7.5 mg
MID, all 13 subjects slept for a variable period of time,
which resulted in signiﬁcantly lower scores of the DSS
than after the 75-lg dose (P<0.05 at times 1, 2, 3, 4 and
6 h). With 75 lg MID, the pre-administration of
ketoconazole did not result in a signiﬁcant decrease of
the scores of the DSS. Finally, with 7.5 mg MID, the
Fig. 1 Concentration proﬁle of midazolam (closed circles), 1-OH-
midazolam (open circles) and 4-OH-midazolam (open triangles)
after oral administration of 75 lg (continuous lines) or 7.5 mg
(dashed lines) midazolam in healthy volunteers without pre-
treatment (left), after rifampicin (middle) and after ketoconazole
pre-treatment (right; the 7.5-mg dose was not given with ketoco-
nazole). Geometric means and standard deviations are shown
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pre-administration of rifampicin resulted in signiﬁcantly
higher scores when compared with the test with 7.5 mg
MID without rifampicin (P<0.01), but only 1 h after
the oral administration of MID.
Table 4 and Table 5 list the correlations measured
between total (conjugated and non-conjugated) MR and
MID clearance, determined after oral administration of
75 lg and 7.5 mg MID, respectively, at various time
points, in the group of subjects with or without pre-
treatment. Thus, 30 min after oral administration of
the low dose, a good correlation (r2=0.64, P<0.001)
was calculated in the group of 13 subjects withoutT
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Fig. 2 Total (unconjugated + conjugated) 1-OH midazolam/
midazolam ratios in function of time after oral administration of
75 lg (open symbols, continuous lines) or 7.5 mg (closed symbols,
dashed lines) midazolam in healthy volunteers without pre-
treatment (circles), after rifampicin (triangles) and after ketoco-
nazole pre-treatment (squares; the 7.5-mg dose was not given with
ketoconazole). Geometric means and standard deviations are
shown
Fig. 3 Results of the Digit Symbol Substitution (DSS) test as a
function of time after oral administration of 75 lg (open symbols,
continuous lines) or 7.5 mg (closed symbols, dashed lines) midazolam
in healthy volunteers without pre-treatment (circles), after rifam-
picin (triangles) and after ketoconazole pre-treatment (squares; the
7.5-mg dose was not given with ketoconazole). Means and standard
deviations are shown (for clarity, only selected standard deviations
bars are represented)
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co-medication, while excellent correlations were calcu-
lated when including subjects with induced and/or
inhibited CYP3A (r2=0.91, P<0.0001 for 13 subjects
without co-medication + 4 subjects with ketoconazole
+ 4 subjects with rifampicin; Table 4). Although being
signiﬁcant when using total MR calculated after
administration of the higher dose of MID (Table 5), the
correlations with MID clearance were lower under
administration of the lower dose. Interestingly, both
after 75 lg and after 7.5 mg MID, much lower correla-
tions were obtained between MID clearance and MR
calculated with unconjugated concentrations of 1OH-
MID. Signiﬁcant correlations were thus observed only
when including subjects with inhibited and/or induced
CYP3A activity, but not when including subjects without
co-medication, and that at all times (data not shown).
We also tried to determine whether MID plasma
levels, determined at various times after administration
of the low and higher dose of MID, can be used to assess
MID clearance (Table 6 and Table 7). It can be seen
Table 4 Spearman correlation coeﬃcients between total 1-OH midazolam/midazolam ratios (determined after oral administration of
75 lg midazolam), and midazolam clearance at various time points and with diﬀerent groups of subjects
0.5 h 1 h 1.5 h 2 h 3 h 4 h 6 h
Subjects without co-medication (n=13)
Spearman correlation 0.80 0.76 0.54 0.68 0.57 0.25 0.46
Coeﬃcient of determination (r2) 0.64 0.58 0.30 0.46 0.32 0.06 0.21
P level <0.001 <0.005 NS (P=0.055) <0.05 <0.05 NS NS
Subjects without co-medication (n=13)
+ subjects with ketoconazole (n=4)
Spearman correlation 0.91 0.89 0.80 0.86 0.80 0.66 0.70
Coeﬃcient of determination (r2) 0.83 0.80 0.63 0.73 0.65 0.44 0.50
P level <0.0001 <0.0001 <0.0005 <0.0001 <0.0005 <0.005 <0.005
Subjects without co-medication (n=13)
+ subjects with rifampicin (n=4)
Spearman correlation 0.91 0.88 0.75 0.82 0.71 0.51 0.46
Coeﬃcient of determination (r2) 0.83 0.77 0.56 0.67 0.51 0.26 0.21
P level <0.0001 <0.0001 <0.001 <0.0005 <0.005 NS (P=0.051) NS
Subjects without co-medication (n=13)
+ subjects with ketoconazole (n=4)
+ subjects with rifampicin (n=4)
Spearman correlation 0.95 0.94 0.87 0.91 0.86 0.76 0.70
Coeﬃcient of determination (r2) 0.91 0.87 0.76 0.82 0.74 0.57 0.50
P level <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0005 <0.005
Table 5 Spearman correlation coeﬃcients between total 1-OH midazolam/midazolam ratios (determined after oral administration of
7.5 mg midazolam) and midazolam clearance at various time points and with diﬀerent groups of subjects
0.5 h 1 h 1.5 h 2 h 3 h 4 h 6 h
Subjects without co-medication (n=13)
Spearman correlation 0.51 0.64 0.63 0.37 0.21 0.29 0.60
Coeﬃcient of determination (r2) 0.26 0.41 0.40 0.14 0.04 0.09 0.35
P level NS (P=0.07) <0.05 <0.05 NS NS NS NS
Subjects without co-medication (n=13)
+ subjects with ketoconazole (n=4)
Spearman correlation 0.78 0.84 0.84 0.72 0.64 0.71 0.87
Coeﬃcient of determination (r2) 0.61 0.71 0.71 0.51 0.42 0.51 0.76
P level <0.0005 <0.0001 <0.0001 <0.005 <0.01 <0.005 <0.0005
Subjects without co-medications (n=13)
+ subjects with rifampicin (n=4)
Spearman correlation 0.78 0.82 0.80 0.65 0.48 0.57 0.60
Coeﬃcient of determination (r2) 0.61 0.68 0.64 0.42 0.23 0.32 0.35
P level <0.0005 <0.0001 <0.0005 <0.01 NS (P=0.07) <0.05 NS
Subjects without co-medication (n=13)
+ subjects with ketoconazole (n=4)
+ subjects with rifampicin (n=4)
Spearman correlation 0.88 0.91 0.90 0.82 0.74 0.80 0.87
Coeﬃcient of determination (r2) 0.78 0.82 0.81 0.67 0.55 0.64 0.76
P level <0.0001 <0.0001 <0.0001 <0.0001 <0.0005 <0.0005 <0.0005
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that, after both doses, excellent correlations were ob-
served between 1.5 h and 4 h for the low doses (r be-
tween )0.81 and )0.85) and between 1.5 h and 6 h for
the higher dose (r between )0.87 and )0.96), in the
subjects without co-medication. As expected, better
correlations were also observed when including the
subjects with ketoconazole and/or rifampicin.
Discussion
The aim of the present study was to determine whether
MID ratios or MID concentrations measured after the
administration of a low dose of MID (75 lg) can be used
to assess CYP3A activity. MID ratios and MID
concentrations measured after the administration of the
low dose were thus correlated with clearance of MID
determined after administration of the therapeutic dose
(7.5 mg) in 13 healthy subjects. Both doses of MID
produced fairly similar pharmacokinetic proﬁles and,
although pharmacokinetic parameters could be
quantiﬁed more accurately with the 7.5-mg dose, they
were also calculated for the 75-lg dose.
To assess whether the 75-lg dose can also be used to
reﬂect intra-individual changes of CYP3A activity, the
pharmacokinetic proﬁle of 75 lg MID was determined
in two groups of four subjects, before and after a
pre-treatment with rifampicin and ketoconazole.
Rifampicin is a strong CYP3A inducer, which has
previously been shown to markedly decrease the blood
concentrations and/or pharmacodynamic eﬀects of
several drugs metabolised by CYP3A, such as MID [16],
alprazolam [17], zolpidem [18], buspirone [19], triazolam
[20] or zopiclone [21]. Ketoconazole is a strong CYP3A
inhibitor which has been shown to increase the blood
concentrations and/or pharmacodynamic eﬀects of
several drugs metabolised by CYP3A, such as MID [22],
triazolam [23, 24] or alprazolam [24].
The pre-treatment by rifampicin had a major inﬂu-
ence on its apparent clearance and distribution volume.
Table 6 Spearman correlation coeﬃcients between midazolam plasma levels (determined after oral administration of 75 lg midazolam)
and midazolam clearance at various time points and with diﬀerent groups of subjects
0.5 h 1 h 1.5 h 2 h 3 h 4 h 6 h
Subjects without co-medication (n=13)
Spearman correlation 0.12 )0.66 )0.85 )0.81 )0. 83 )0.83 )0.63
Coeﬃcient of determination (r2) 0.01 0.43 0.73 0.66 0.69 0.68 0.40
P level NS <0.05 <0.0005 <0.001 <0.0005 <0.005 NS
Subjects without co-medication (n=13)
+ subjects with ketoconazole (n=4)
Spearman correlation )0.50 )0.84 )0.93 )0.91 )0.92 )0.93 )0.91
Coeﬃcient of determination (r2) 0.25 0.70 0.86 0.84 0.85 0.86 0.82
P level <0.05 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0005
Subjects without co-medication (n=13)
+ subjects with rifampicin (n=4)
Spearman correlation )0.27 )0.77 )0.90 )0.87 )0.83 )0.83 )0.63
Coeﬃcient of determination (r2) 0.07 0.59 0.82 0.76 0.69 0.68 0.40
P level NS <0.001 <0.0001 <0.0001 <0.0005 <0.005 NS
Subjects without co-medications (n=13)
+ subjects with ketoconazole (n=4)
+ subjects with rifampicine (n=4)
Spearman correlation )0.64 )0.88 )0.95 )0.94 )0.92 )0.93 )0.91
Coeﬃcient of determination (r2) 0.41 0.77 0.90 0.88 0.85 0.86 0.82
P level <0.005 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0005
Table 7 Spearman correlation coeﬃcients between midazolam plasma levels (determined after oral administration of 7.5 mg midazolam)
and midazolam clearance at various time points and with diﬀerent groups of subjects
0.5 h 1 h 1.5 h 2 h 3 h 4 h 6 h
Subjects without co-medication (n=13)
Spearman correlation )0.08 )0.51 )0.87 )0.91 )0.87 )0.96 )0.86
Coeﬃcient of determination (r2) 0.01 0.26 0.75 0.83 0.76 0.91 0.74
P level NS NS (P=0.07) <0.0005 <0.0001 <0.0001 <0.0001 <0.0005
Subjects without co-medication (n=13)
+ subjects with rifampicin (n=4)
Spearman correlation )0.59 )0.76 )0.93 )0.94 )0.91 )0.96 0.11
Coeﬃcient of determination (r2) 0.35 0.58 0.86 0.89 0.84 0.93 0.01
P level <0.05 <0.0005 <0.0001 <0.0001 <0.0001 <0.0001 NS
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This is ﬁrst explained by a pronounced negative eﬀect on
MID bioavailability, which increases the denominator of
the apparent value of both those parameters. Rifampicin
increases CYP3A4 activity both in the liver and in the
bowel wall [16]. The absence of change in MID terminal
t1/2 with the therapeutic dose in response to rifampicin
cannot be explained by a too-short period during which
MID was quantiﬁed. On the contrary, the early dispo-
sition of MID was characterised by a steeper slope after
rifampicin pretreatment; this observation is in line with
authors having reported a shortening of MID t1/2 under
rifampicin (from 3.1 h to 1.3 h), using a less sensitive
assay and a shorter period of blood collection [16]. In
the present study, the slope of the terminal part of the
disposition curve was not signiﬁcantly inﬂuenced by
rifampicin. One could imagine that this late phase re-
ﬂects a slow redistribution of MID from a deep com-
partment. It must also be mentioned that a higher dose
of rifampicin (600 mg/day) was used in the previous [16]
than in the present study (450 mg/day). Changes ob-
served in the apparent pharmacokinetic parameters of
1OHMID and 4OHMID are more diﬃcult to interpret.
These values are under the dependence of the oral bio-
availability, but they also reﬂect changes induced by
rifampicin in the metabolic fraction corresponding to
the respective pathway. This is illustrated by the
important increase in the plasma ratio of 1OHMID over
MID.
The eﬀect of ketoconazole on MID kinetics was op-
posed to that of rifampicin as reported in a previous
study [22]. The decrease of the apparent clearance and
distribution volume is mainly mediated by an increase of
MID bioavailability. As the relative decrease in appar-
ent distribution volume was less than in apparent
clearance, this suggests an alteration of the true clear-
ance in addition to the eﬀect on bioavailability. The
prolongation of MID t1/2 by ketoconazole observed in
the present study is also in agreement with previously
published results [22]. However, a much stronger
increase (5.5-fold increase versus 1.6-fold) was found in
the latter study [22], which could tentatively be explained
by a longer blood sampling period (24 h). The t1/2 of
1OHMID and 4OHMID appeared prolonged too, but
this is probably an indirect eﬀect, the disposition of these
metabolites being driven by their production.
The present study shows that the 30 min MR can be
reliably used as an indicator of MID clearance and, thus,
of CYP3A activity. In the group of 13 subjects with non-
induced and non-inhibited CYP3A activity, the MR
accounts for 64% of the variability of MID clearance. In
the group of 17 subjects including either four subjects
with induced or four subjects with reduced CYP3A4
activity, the MR accounts for 83% of its variability,
while in the group of 21 subjects, including four subjects
with induced and four subjects with reduced CYP3A
activity, the 30-min MR accounts for 91% of its
variability. This result conﬁrms those of previously
published studies, although in the latter only the higher
dose of MID was used [7, 9, 10, 11, 12]. In fact,
unexpectedly, better correlations were obtained with the
lower than with the higher dose, which however needs to
be conﬁrmed by other studies. The present study also
shows that MR calculated with total concentrations
(unconjugated + conjugated) is a better indicator of
CYP3A activity than MR calculated with unconjugated
concentrations. This result can most probably be ex-
plained by the fact that the use of total concentrations,
determined after enzymatic hydrolysis of the glucuronic
conjugates, allows removal of the interindividual vari-
ability of glucuroconjugation from the MR [9].
The present study also shows that MID plasma
levels can be used as an indicator of MID presystemic
metabolism, after both the lower and higher doses.
However, only values measured from 90 min up to 4–
6 h can be used reliably. This result is in agreement
with those of another study that attempted to validate
the use of alprazolam as a CYP3A test probe, and that
found excellent correlations between alprazolam plas-
ma concentrations measured 6, 8, 10 and 24 h after
oral administration of a therapeutic dose of alprazolam
(i.e. 1 mg) and AUC of this drug [17]. It is also in
agreement with those of a recent retrospective study
suggesting that, following an IV or oral MID admin-
istration, the optimal single sampling time to predict
AUC was between 3 h and 4 h [13]. The question arises
whether only intestinal or both intestinal and hepatic
CYP3A are assessed by the use of such a low dose of
MID; the fact that good correlations are observed
between MID clearance measured after the 7.5-mg dose
and the 30-min MR or the MID plasma levels measured
after the 75-lg dose is an argument supporting the latter
hypothesis.
In summary, the present study shows that a low oral
dose of MID (75 lg) can be reliably used to assess
CYP3A activity. This can be performed either by the
determination of the 30-min MR calculated with total
(unconjugated + conjugated) concentrations or by
measuring MID plasma levels between 1.5 h and 4 h
after oral intake. Due to the lack of central nervous
system side eﬀects induced by this low dose, even in
subjects with a low CYP3A activity, and due to its short
duration (in particular when using the MR), this test can
easily be used for large-scale phenotyping tests.
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